olanzapine/fluoxetine / Generic mfg. - LARVOL DELTA

National Pregnancy Registry for Psychiatric Medications (clinicaltrials.gov) - P=N/A | N=5000 | Recruiting | Sponsor: Massachusetts General Hospital

Trial completion date • Trial primary completion date • Psychiatry

Bipolar disorder in children, adolescents and young adults. Part 2. Therapeutic management. Recommendations under the patronage of the Executive Board of the Polish Psychiatric Association, National Consultants in the field of Psychiatry and National Consultants in Child and Adolescent Psychiatry. (PubMed, Psychiatr Pol) - "Lithium, aripiprazole, quetiapine, risperidone, olanzapine, asenapine, ziprasidone are recommended for the treatment of mania and mixed states. For the treatment of depressive episodes in bipolar disorder in children and adolescents, experts recommend lurasidone as monotherapy or olanzapine + fluoxetine as combination therapy. Although long-term treatment is a key aspect of bipolar disorder management in children and adolescents, consistent efficacy data are still lacking. Safety data indicate that the most commonly reported adverse reactions in children and adolescents treated with mood stabilizers are gastrointestinal and neurological adverse reactions, while the use of antipsychotics is mainly associated with weight gain and sedation."

Clinical guideline • Journal • Review • Anesthesia • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

CASE PRESENTER 2: LIMITED-RESOURCE SETTINGS AND A COMPLEX PSYCHIATRIC CASE: PSYCHOTIC BIPOLAR DEPRESSION WITH CATATONIA (WPA-WCP 2025) - "These included lamotrigine, quetiapine, alprazolam, biperiden, lorazepam (up to 12mg/day), fluoxetine, olanzapine, amantadine, aripiprazole, and clozapine. This case highlights the complexity of managing catatonia when significant psychotic symptoms are present, weighing the benefits and risks of psychoactive drugs. Additionally, a late brain magnetic resonance image showed an arachnoid cyst and microangiopathy, findings that could or not be involved in the patient's clinical presentation."

Clinical • Bipolar Disorder • CNS Disorders • Depression • Insomnia • Mood Disorders • Psychiatry • Sleep Disorder

Fixed dose combination dextromethorphan-bupropion: A hope for treatment resistant depression (TRD). (PubMed, Indian J Psychiatry) - "Olanzapine-fluoxetine combination, rTMS, Intravenous ketamine and Electroconvulsive therapy have been till now studied in TRD. Dextromethorphan-bupropion is a newer antidepressant, which has been found to be effective, fast-acting, and well tolerated medicine for depression. We used this novel antidepressant in three cases of TRD, alone and with combination, and it showed satisfactory response within 2 weeks."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Atypical Antipsychotics in Mood and Other Disorders: Are We Too Quick on the Draw? - A Panel Discussion (APA 2025) - "Following the 1989 advent of SGAs when clozapine was launched, these medications began their triumphant march across the pages of the DSM: prescribed on-label for Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression augmentation, irritability associated with Autism Spectrum Disorder, suicidal risk reduction; off-label for PTSD, sleep disorders, ADHD, Tourettes Disorder, OCD, panic disorder, eating disorders, and both on label and off label - depending on which SGA - agitation associated with Alzheimer's.`...In the 1960s and 70s there were several formulations which combined first generation antipsychotics with antidepressants in a single pill (e.g., amitriptyline+perphenazine, tranylcypromine+trifluoperazine.) Although these combinations are still available, they seemed to fall out of favor in the 1980s, perhaps as a result of increasing attention to the challenge of tardive dyskinesia and the increasing faith in newer antidepressants. (We..."

ADHD (Impulsive Aggression) • Alzheimer's Disease • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • Bipolar Disorder • CNS Disorders • Depression • Genetic Disorders • Major Depressive Disorder • Mood Disorders • Movement Disorders • Post-traumatic Stress Disorder • Psychiatry • Schizophrenia • Sleep Disorder • Tourette Syndrome

Electroconvulsive Therapy and the Onset of Diabetes: A Rare but Critical Complication in Children (ESPE-ESE 2025) - "Case Presentation A 13-year-old boy with early-onset psychosis and treatment-resistant ADHD had been on medication, including fluoxetine, olanzapine, quetiapine, and mianserin for the past two months. Conclusion Considering the uncertainty surrounding the etiology of childhood psychiatric disorders and the potential impact of ECT on glycemic control,the effect of ECT on beta cell reserve in children should be further evaluated. A multidisciplinary approach is essential during the ECT treatment process in children, with careful attention to hyperglycemic complications and more frequent monitoring of blood glucose levels."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Diabetes • Infectious Disease • Measles • Mental Retardation • Metabolic Disorders • Ocular Inflammation • Ophthalmology • Pediatrics • Psychiatry

An Overview of Psychiatric Disorders and Treatment in Patients with Lennox-Gastaut Syndrome in a LATAM Specialized Center (AAN 2025) - "Psychotropic medications were administered to 24 patients (60%), with 5 (12.5%) receiving risperidone as monotherapy, followed by sertraline in 3 (7.5%), fluoxetine in 2 (5%), and clonazepam, haloperidol, and quetiapine in 1 (2.5%) each. Additionally, polytherapy was utilized, including risperidone with SSRIs in 3 (7.5%) and fluoxetine with olanzapine in 2 (5%).The most common comorbidity was intellectual developmental impairments. The most common comorbidity was intellectual developmental impairments. Moreover, half of the patients had psychiatric comorbidities, with behavioral disturbances and psychosis being the most common, as documented in literature. This highlights the importance of early diagnosis and treatment, as these conditions worsen prognosis."

Clinical • CNS Disorders • Depression • Epilepsy • Mental Retardation • Psychiatry • Sleep Disorder

Ecofriendly and smart spectrophotometric approaches for synchronized analysis of two antipsychotic drugs, fluoxetine and olanzapine: application to combined tablet dosages with assessment of method greenness. (PubMed, BMC Chem) - "In conclusion, for FLX determination, the use of dual wavelength method is preferable because it needs very low mathematical treatment than the ratio subtraction method. However, for OLZ, the ratio subtraction method has higher sensitivity than absorptivity factor method although the latter is simpler."

Journal • CNS Disorders

Quantitative Evaluation of Multiple Treatment Regimens for Treatment-Resistant Depression. (PubMed, Int J Neuropsychopharmacol) - "The quantitative evaluation of 22 TRD treatments illuminates key pharmacodynamic parameters, bolstering the development of clinical guidelines and aiding the design of clinical trials and medical decision-making."

Journal • CNS Disorders • Depression • Mood Disorders • Pain • Psychiatry

The efficacy of valproate in acute mania, bipolar depression and maintenance therapy for bipolar disorder: an overview of systematic reviews with meta-analyses. (PubMed, BMJ Open) - "This overview highlights favourable results for valproate compared with placebo in all phases of BD, as well as presenting specific results in comparison with other active drugs. However, these results must be interpreted considering the methodological limitations of our study."

Clinical • Journal • Review • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Youth With Bipolar Disorder: Pharmacologic Interventions and Strategies to Mitigate Adverse Effects (AACAP 2024) - "Lurasidone and olanzapine-fluoxetine combination are the only evidence-based US FDA-approved treatments for depression associated with bipolar disorder in youth... SGAs and lithium are evidence-based treatments for youth with bipolar disorder. Metabolic burden varies among SGAs and should inform treatment selection. Education regarding side effects, as well as healthy lifestyle intervention and metformin, should be considered as part of all antipsychotic treatment regimens."

Adverse events • Bipolar Disorder • CNS Disorders • Depression • Metabolic Disorders • Mood Disorders • Psychiatry

Spectrophotometric determination of olanzapine, fluoxetine HCL and its impurity using univariate and chemometrics methods reinforced by latin hypercube sampling: Validation and eco-friendliness assessments. (PubMed, BMC Chem) - "Statistical analysis revealed no noteworthy differences (P > 0.05) among the proposed and published techniques. Both pure powders and pharmaceutical capsules were analyzed via these methods."

Journal

LEGIONELLA TRIAD: A RARE PRESENTATION OF LEGIONNAIRES' DISEASE (CHEST 2024) - "He had been residing in a shelter and had a history of anxiety and depression, for which he was prescribed fluoxetine and olanzapine...The patient received aggressive hydration and levofloxacin at a dosage appropriate for patients with renal impairment... This case report highlights a distinct presentation of legionnaires disease associated rhabdomyolysis and acute renal failure and the need to maintain a high degree of suspicion for legionella pneumonia even in patients without classic symptoms like fever, especially for high-risk individuals like those residing in shelters. Our patient was successfully treated with aggressive hydration and appropriate antibiotics and didn't require initiation of hemodialysis, emphasizing the need for early recognition and prompt initiation of treatment."

Acute Kidney Injury • CNS Disorders • Cough • Depression • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Influenza • Musculoskeletal Pain • Nephrology • Novel Coronavirus Disease • Pain • Pneumococcal Infections • Pneumonia • Psychiatry • Renal Disease • Respiratory Diseases

Predicting remission after acute phase pharmacotherapy in patients with bipolar I depression: A machine learning approach with cross-trial and cross-drug replication. (PubMed, Bipolar Disord) - "Machine learning strategies achieved cross-trial and cross-drug replication in predicting remission after 8 weeks of pharmacotherapy for BP-D. Interpretable prognoses rules required only a limited number of depressive symptoms, providing a promising foundation for developing simple quantitative decision aids that may, in the future, serve as companions to clinical judgment at the point of care."

Journal • Machine learning • Bipolar Disorder • CNS Disorders • Depression • Infectious Disease • Mood Disorders • Psychiatry

Rolling the dice with aripiprazole: an adolescent case report of gambling disorder associated with aripiprazole (ECNP 2024) - "She was first treated with fluoxetine and olanzapine...She was then referred to an addiction unit and aripiprazole was discontinued and switched to risperidone...In the majority of cases, the symptoms appeared within 30 days after aripiprazole administration started and ceased within 30 days of its discontinuation and/or dose decrease.[5] Conclusion :The consequences of GD on social life, family and health may be serious. Clinicians should be aware about the possible gambling and other impulse-control behaviors in patients taking aripiprazole and educate both patients and the family about these risks."

Case report • Clinical • Anorexia • CNS Disorders • Psychiatry • Tobacco Addiction

Atypical depression, borderline personality disorder and bipolar disorder: discussing a challenging diagnosis with a case report (ECNP 2024) - "Since her first psychiatry appointment, at the age of 15, she started treatment with Escitalopram...While at the impatient unit, she responded well to treatment with Fluoxetine and Olanzapine, with remission of her depressive symptoms, intrusive thoughts of self-criticism and death... In this paper, through a case report, we discuss the considerable commonality in the clinical symptoms and long-term traits between atypical depression, borderline personality disorder and bipolar disorder. This patient showed symptoms of atypical depression (reactive mood, marked anergia, reverse vegetative symptoms as increased appetite and hypersomnia and a trait of exaggerated vulnerability) [3] comorbid with borderline personality disorder (constant affective instability of high intensity, unstable self-image with self-harming behaviours). Because of the "atypicality" of her depressive symptoms, there was a high index of suspicion of cyclothymic temperament (favored by her..."

Case report • Clinical • Bipolar Disorder • Borderline Personality Disorder • CNS Disorders • Depression • Mood Disorders • Personality Disorder • Psychiatry • Sleep Disorder

PSD-AOFC: Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: All India Institute of Medical Sciences, Bhubaneswar | Recruiting ➔ Completed

Trial completion • CNS Disorders • Depression • Mood Disorders • Psychiatry • Schizophrenia

Treatment of bipolar depression: clinical practice vs. adherence to guidelines-data from a Bavarian drug surveillance project. (PubMed, Front Psychiatry) - "Of the patients, 38% were not administered any drug explicitly recommended for treatment of BPD, that is, quetiapine, lamotrigine, carbamazepine, or olanzapine...Prescription rates of venlafaxine (21% to 14%) and tricyclic antidepressants (9% to 6%) decreased significantly from the first (2014-2016) to the last (2020-2022) observed time period...Only two patients were administered a combination of olanzapine and fluoxetine...Increase in lithium prescription is an encouraging development due to its unique efficacy in maintenance treatment. To improve the quality of clinical practice guideline implementation, more randomized controlled trials should be conducted in the future to prospectively investigate different implementation strategies."

Adherence • Journal • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Eating Disorders in Patients with Bipolar Disorders- Therapeutic Challenges and Case Management Strategies (ISBD 2024) - "According to another review, olanzapine or risperidone are recommended for manic episodes in the presence of ED, and olanzapine +/- fluoxetine or lamotrigine for bipolar depression + ED... The ED-BD comorbidity increases the difficulty of case management, and closer therapeutic monitoring is required. The regular use of plasma drug levels and psychotherapy are useful interventions for this population."

Clinical • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

The Black Book of Psychotropic Dosing and Monitoring. (PubMed, Psychopharmacol Bull) - "The combination of dextromethorphan 45 mg twice per day and bupropion SR 105 mg twice daily appears to be more effective than an equivalent dose of bupropion alone both in speeding up antidepressant response and achieving remission...The phase III program for Auvelity, showed that the drug was well tolerated with the most common side effects being dizziness, headache, and dry mouth.86 Another novel antidepressant agent approved in 2023 is zuranolone (Zurzuvae)...Zuranolone's, as does brexanolone, is thought to act primarily as allosteric modulator of the GABA-a receptors...Gepirone is not exactly a new or novel antidepressant and originally sought approval in the US about 20 years ago.88 There had been two positive studies of gepirone during the original NDA application but also a number of failed, negative, or non-informative studies as well...Second generation antipsychotics (SGAs) continue to be the only class of agents [other than esketamine (Spravato)] approved..."

Journal • Review • Addiction (Opioid and Alcohol) • Alzheimer's Disease • Anesthesia • CNS Disorders • Constipation • Depression • Fatigue • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Insomnia • Major Depressive Disorder • Mental Retardation • Mood Disorders • Pain • Postpartum Depression • Post-traumatic Stress Disorder • Psychiatry • Schizophrenia • Sleep Disorder • Xerostomia

Update on Treatment Resistant Depression (WFSBP 2024) - "Intravenous ketamine and intranasal esketamine (co-administered with an antidepressant) are established as efficacious in the management of TRD. Several second-generation antipsychotics (e.g., aripiprazole, brexpiprazole, cariprazine, quetiapine XR) are proven effective as antidepressant augmentation treatments in partial responders, but only the olanzapine-fluoxetine combination has been studied in FDA-defined TRD...Non-üphasrmacological treatment options are also available including both psychotherapy as well as ECt or TMS. There is as yet no clear distinction in the algorithm when to place these treatment modalities."

CNS Disorders • Depression • Mood Disorders • Psychiatry

Modafinil / Armodafinil in Bipolar Disorder: Lesson Learned, Roadmap Forward (ASCP 2024) - "bimodal mood stabilization quetiapine, cariprazine), were co-prescribed with an antimanic agent (i.e. olanzapine fluoxetine combination), or generally assumed to have antimanic properties as a class effect in bipolar disorder (i.e. lurasidone, lumataperone). Better understand design challenges in a non-mood stabilizer being investigated for bipolar depression 2. Appreciate subtypes of bipolar depression that may prove useful for subsequent narrower investigation Literature"

Bipolar Disorder • CNS Disorders • Cognitive Disorders • Depression • Mood Disorders • Narcolepsy • Psychiatry • Sleep Disorder

Do Second Generation Antipsychotics Protect Against the Emergence of (Hypo)mania in Depressed Patients with Mixed Features? (ASCP 2024) - "Background: Currently, 5 medications have been approved for the treatment of bipolar depression: quetiapine, olanzapine/fluoxetine combination, cariprazine, lurasidone, and lumateperone. The presence of mixed features is associated with an increased risk of a switch into a (hypo)manic episode in patients with bipolar depression who are treated with antidepressants. Given the more general risk of a (hypo)manic switch, we wondered if medications proven effective in treating bipolar depression might be protective against such a switch. The results of the present analysis suggest that the second generation antipsychotics that are effective in treating bipolar depression protect against a (hypo)manic switch in patients with mixed features."

Clinical • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Pediatric Bipolar Depression: Challenges in the diagnosis and treatment (APA 2024) - "Conclusions Depression in the context of BD in youth may be particularly responsive to psychotherapeutic interventions, potentially more so than mania. Common themes of these interventions are psychoeducation, behavioral and cognitive interventions, including reducing stress and improving coping strategies, and mood regulation techniques Pharmacologic management of bipolar depression is very difficult, olanzapine-fluoxetine and lurasidone significantly reduced depressive symptoms in children and adolescents with Bipolar I depression v"

Clinical • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Pediatrics • Psychiatry

Pharmacological Approaches to Treatment-Resistant Depression (TRD) (APA 2024) - "A number of atypical antipsychotic agents, such as aripiprazole, quetiapine, brexpiprazole and cariprazine, are FDA-approved for the treatment of depressed patients with inadequate response to antidepressants. Both the combination of olanzapine and fluoxetine and the intranasal esketamine are approved for treatment resistant depression...Objective Three: The participant will learn about to best select these interventions based on the clinical characteristics of the depressed patients and their level of resistance. Objective Four: Objective Five:"

CNS Disorders • Depression • Mood Disorders • Psychiatry